Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Current Liabilities: 2012-2025

Historic Total Current Liabilities for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to $866.2 million.

  • Ptc Therapeutics' Total Current Liabilities rose 41.84% to $866.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $866.2 million, marking a year-over-year increase of 41.84%. This contributed to the annual value of $581.0 million for FY2024, which is 3.67% down from last year.
  • Ptc Therapeutics' Total Current Liabilities amounted to $866.2 million in Q3 2025, which was up 37.98% from $627.8 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Total Current Liabilities peaked at $866.2 million during Q3 2025, and registered a low of $250.9 million during Q1 2021.
  • In the last 3 years, Ptc Therapeutics' Total Current Liabilities had a median value of $595.4 million in 2025 and averaged $589.0 million.
  • Examining YoY changes over the last 5 years, Ptc Therapeutics' Total Current Liabilities showed a top increase of 95.00% in 2022 and a maximum decrease of 20.24% in 2022.
  • Ptc Therapeutics' Total Current Liabilities (Quarterly) stood at $509.3 million in 2021, then declined by 20.24% to $406.2 million in 2022, then skyrocketed by 48.46% to $603.1 million in 2023, then declined by 3.67% to $581.0 million in 2024, then soared by 41.84% to $866.2 million in 2025.
  • Its last three reported values are $866.2 million in Q3 2025, $627.8 million for Q2 2025, and $595.4 million during Q1 2025.